Microbiome Report for Week Ending 4/6/19

C3J Therapeutics, Inc. (C3J) a private clinical stage biotechnology company focused on the development of novel targeted antimicrobials based on bacteriophage,  announced on 4/2/19 that the United States Patent and Trademark Office (USPTO) has issued patent No. 10,221,398, entitled “Compositions of and Methods for In Vitro Viral Genome Engineering.”